Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT.

Lancet. 2002 Mar 2;359(9308):727-32.

PMID:
11888582
2.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR.

Clin Infect Dis. 2007 Jun 1;44(11):1503-8. Epub 2007 Apr 18.

PMID:
17479950
3.

[HLA-B*5701 and abacavir hypersensitivity reaction].

Servonnet A, Leclercq E, Delacour H, Ceppa F.

Pathol Biol (Paris). 2010 Dec;58(6):e95-100. doi: 10.1016/j.patbio.2008.12.001. Epub 2009 Feb 24. French.

PMID:
19243901
4.

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S.

Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5. Epub 2004 Mar 15.

5.

Current trends in screening across ethnicities for hypersensitivity to abacavir.

Rodriguez-Nóvoa S, Soriano V.

Pharmacogenomics. 2008 Oct;9(10):1531-41. doi: 10.2217/14622416.9.10.1531.

PMID:
18855539
6.

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

Pérez Prior N, Rocher Milla A, Soler Company E, Flores Cid J, Sarria Chust B.

Farm Hosp. 2009 May-Jun;33(3):155-60. Spanish.

PMID:
19712599
7.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

8.

HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.

Dvali N, Chkhartishvili N, Sharvadze L, Karchava M, Tsertsvadze T.

Georgian Med News. 2010 Dec;(189):16-20.

PMID:
21252404
9.

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M.

Pharmacogenetics. 2004 Jun;14(6):335-42.

PMID:
15247625
10.

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

Lalonde RG, Thomas R, Rachlis A, Gill MJ, Roger M, Angel JB, Smith G, Higgins N, Trottier B.

Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 2009 Oct 15.

PMID:
19843279
11.

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD.

Lancet. 2002 Mar 30;359(9312):1121-2.

PMID:
11943262
12.

Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.

Giorgini S, Martinelli C, Tognetti L, Carocci A, Giuntini R, Mastronardi V, Torricelli F, Leoncini F, Lotti T.

Dermatol Ther. 2011 Nov-Dec;24(6):591-4. doi: 10.1111/j.1529-8019.2012.01409.x.

PMID:
22515676
13.

Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.

Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, Chang SC.

J Antimicrob Chemother. 2007 Sep;60(3):599-604. Epub 2007 Jul 12.

PMID:
17631508
14.

Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.

Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K, Silva-Zolezzi I, Fernandez-Lopez JC, Jimenez-Sanchez G, Carnevale A.

Pharmacogenomics. 2011 Jun;12(6):809-14. doi: 10.2217/pgs.11.31. Epub 2011 Apr 21.

PMID:
21510768
15.

Cytokine profiling in abacavir hypersensitivity patients.

Almeida CA, Martin AM, Nolan D, Lucas A, Cameron PU, James I, Phillips E, Mallal S.

Antivir Ther. 2008;13(2):281-8.

PMID:
18505179
16.

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

Waters LJ, Mandalia S, Gazzard B, Nelson M.

AIDS. 2007 Nov 30;21(18):2533-4.

PMID:
18025891
18.

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.

Siljic M, Salemovic D, Cirkovic V, Pesic-Pavlovic I, Todorovic M, Ranin J, Dragovic G, Jevtovic D, Stanojevic M.

Intervirology. 2017;60(1-2):43-47. doi: 10.1159/000477810. Epub 2017 Aug 4.

PMID:
28772259
19.

Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.

Moragas M, Belloso WH, Baquedano MS, Gutierrez MI, Bissio E, Larriba JM, Fay F, Aulicino P, Gurevich JM, Yaunguzian MF, Maldonado AC, Falistocco C, Sen L, Mangano A.

Tissue Antigens. 2015 Jul;86(1):28-31. doi: 10.1111/tan.12575. Epub 2015 Apr 29.

PMID:
25922880
20.

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S.

Clin Infect Dis. 2006 Jul 1;43(1):99-102. Epub 2006 May 26.

Supplemental Content

Support Center